Cara Therapeutics (CARA) Reports In-Line Q3 EPS
Tweet
Share
E-mailGet Alerts CARA Hot Sheet
Join SI Premium – FREE
Cara Therapeutics (NASDAQ: CARA) reported Q3 EPS of ($0.52), in-line with the analyst estimate of ($0.52). Revenue for the quarter came in at $4.87 million versus the consensus estimate of $9.95 million.
For earnings history and earnings-related data on Cara Therapeutics (CARA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sprout Social (SPT) Tops Q2 EPS by 10c ; Offers Guidance
- Nutex Health (NUTX) Tops Q2 EPS by 450c
- ICU Medical (ICUI) Tops Q2 EPS by 46c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
